Beijing Chao-Yang Hospital
首都医科大学附属北京朝阳医院
Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Beijing Chao-Yang Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
- Hepatocellular carcinoma肝细胞癌18 papers led
- Stomach cancer胃癌12 papers led
- Chordoma脊索瘤2 papers led
- Osteosarcoma骨肉瘤6 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
- Neuroblastoma神经母细胞瘤1 paper led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤52 papers led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征0 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
- Takayasu arteritis大动脉炎3 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化12 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病4 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎3 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
- Congenital diaphragmatic hernia先天性膈疝1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led8
- p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.
- Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.
- Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.
- Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.
- Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis.
- APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.
- High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.
- DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.
More papers found outside PubMed (not counted)12
- 193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma
- Data from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway
- Supplementary Figure 4 from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway
- Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling
- Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
Cancer
Hepatocellular carcinoma
肝细胞癌Led 18 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led18
- Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.
- LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.
- Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.
- Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway.
- Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein.
- Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
- Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.
- Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.
- Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.
- Prognosis of Liver Transplantation for Hepatocellular Carcinoma in Terms of Different Criteria: A Single Center Experience.
- Anatomic resection versus radiofrequency ablation with an ablative margin ≥ 1.0 cm for solitary small hepatocellular carcinoma measuring ≤ 3 cm: Comparison of long-term outcomes using propensity score matching analysis.
- Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.
- Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
- Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
- Intrahepatic hemorrhage and recurrence caused by arterioportal fistula after radiofrequency ablation for hepatocellular carcinoma: A thought-provoking ablation-related complication.
- The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
- PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Cancer
Stomach cancer
胃癌Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Lipidomic machine learning predictor for progression of gastric cancer.
- Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma.
- Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.
- GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
- Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.
- Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.
- DNA methylation profiling identifies epigenetic signatures of early gastric cancer.
- Multimodality Therapy, Followed by Laparoscopic Gastrectomy, for Unresectable Gastric Cancer With Outlet Obstruction and Bulky N2 Metastases.
- Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.
- Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens.
- Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.
- Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chinese-language papers (not in the count)6
- [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].
- [Clinicopathological features of Helicobacter pylori-negative early gastric cancer].
- [The value of Alcian blue periodic acid Schiff staining and Ki-67 expression in diagnosing gastric reactive epithelial hyperplasia and dysplasia].
- [Clinicopathological features of early gastric cancer after Helicobacter pylori eradication].
- [Clinicopathological features of very well-differentiated adenocarcinoma of the stomach].
- [Application and Progress of Convolutional Neural Network-based Pathological Diagnosis of Gastric Cancer].
All its trials on ClinicalTrials.gov, any status5
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
Cancer
Chordoma
脊索瘤Led 2 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 1.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Osteosarcoma
骨肉瘤Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- miR-486-3p Suppresses Osteosarcoma Proliferation and Migration by Targeting the SPRED1-MAPK/ERK Pathway.
- Research progress on cancer-associated fibroblasts in osteosarcoma.
- Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma.
- Prognostic Signature in Osteosarcoma Based on Amino Acid Metabolism-Associated Genes.
- 18F-FDG PET/CT of Primary Extraskeletal Ewing Sarcoma of the Prostate.
- LncRNA LINC00958 promotes tumor progression through miR-4306/CEMIP axis in osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 52 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 3.1%.
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 14
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an
- RecruitingStudy to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT07529782
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07620275
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General Hospital; 2 listed hospitals as study sitesBeijing, Tianjin
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07297329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06508983
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-06
- Registry
- NCT06574568
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou
- RecruitingSafety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05565807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Phase
- Phase 3
- Started
- 2022-09
- Registry
- NCT05243797
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
- Not yet recruitingStudy of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 2
- Started
- 2027-12
- Registry
- NCT07695740
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingClinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 3
- Started
- 2026-06
- Registry
- NCT07569757
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led52
- Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.
- The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.
- Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.
- Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients.
- Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.
- Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.
- Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.
- Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.
- Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
- Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma.
- Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
- Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.
- Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
- KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma.
- Detection of lenalidomide metabolites in urine to discover drug-resistant compounds.
- Proteomics analysis of serum and urine identifies VCP and CTSA as potential biomarkers associated with multiple myeloma.
- Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.
- Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.
- Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.
- Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.
- Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.
- Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
- Wound healing after surgical therapy for multiple myeloma: a case-control study.
- Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.
- The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.
- Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
- Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
- Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.
- Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.
- In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.
- Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
- Biological research on the occurrence and development of multiple myeloma and its treatment.
- The effects of nutritional support on cellular immunity of the patient with multiple myeloma undergoing chemotherapy.
- Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
- Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
- Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.
- Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.
- Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
- Routine blood biomarkers for the detection of multiple myeloma using machine learning.
- The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.
- Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.
- The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
- Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.
- Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.
- The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.
- A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
- Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.
- At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
- Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
- LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN.
- Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.
Chinese-language papers (not in the count)20
- [The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].
- [Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].
- [Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].
- [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].
- [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].
- [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].
- [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].
- [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].
- [Minimal residual disease assessment and progress in multiple myeloma].
- [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1].
- [Application and significance of peripheral blood circulating plasma cells in the diagnosis of multiple myeloma].
- [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].
- [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].
- [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].
- [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].
- [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].
- [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].
- [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].
- [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].
- [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].
All its trials on ClinicalTrials.gov, any status45
- Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
- CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma
- Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients
- Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients
- Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- A Study of Daratumumab
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- A Study of TQB3820 in Patients With Hematological Malignancies
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
- Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for beta thalassaemia157 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Blood disorders
Atypical haemolytic uraemic syndrome
非典型溶血性尿毒症综合征Led no English-language PubMed papers on atypical haemolytic uraemic syndrome in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome
No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Takayasu arteritis
大动脉炎Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.
- Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement.
- Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu's arteritis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)3
- Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China.
- [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].
- [The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 12 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.
- Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.
- Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.
- Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.
- Cluster features in fibrosing interstitial lung disease and associations with prognosis.
- Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.
- MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.
- Characteristics of Chest HRCT and pulmonary function tests in elderly-onset primary Sjögren syndrome with interstitial lung disease.
- TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.
- Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.
- Air pollution and hospitalization of patients with idiopathic pulmonary fibrosis in Beijing: a time-series study.
- Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)21
- Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.
- HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.
- Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.
- Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death.
- [Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].
- [A concise review of telomere and telomerase-related genetic markers in fibrotic lung diseases].
- Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.
- Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.
- Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.
- A Rare Missense Variant in Telomerase Reverse Transcriptase is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family.
- Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.
- Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".
- Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.
- Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
- [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].
- Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis.
- Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.
- [Clinical features of acute diffuse pulmonary exudative disorders].
- [Differentially expressed genes analysis in expression profile data of pulmonary fibrosis with pulmonary hypertension].
- Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.
- miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.
All its trials on ClinicalTrials.gov, any status8
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
IgA nephropathy
IgA 肾病Led 4 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Causal relationship between gastroesophageal reflux disease and IgA nephropathy: a Mendelian randomization analysis.
- Efficacy and safety of low-dose corticosteroids combined with leflunomide for progressive IgA nephropathy: a systematic review and meta-analysis.
- Transcriptomic analysis reveals the potential crosstalk genes and immune relationship between IgA nephropathy and periodontitis.
- Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 3 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.
- Comparative diagnostic efficacy of two-dimensional shear wave and transient elastography in predicting the risk of esophagogastric varices and histological staging in patients with primary biliary cholangitis.
- Association between autoimmune liver diseases and chronic hepatitis B: A multivariable Mendelian randomization study in European population.
Earlier papers (2016–2020)1
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Beijing for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other linked evidence
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京朝阳医院
Beijing Chao-Yang Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Beijing Chaoyang Hospital; Beijing Chao-yang Hospital; Beijing Chaoyang Hospital Affiliated to Capital Medical University; Myeloma Research Center of Beijing Beijing Chao-Yang Hospital; Beijing Chao-yang Hospital Affiliated with Capital Medical University; Beijing Chao-yang Hospital Affiliated to Capital Medical University; Beijing Chaoyang Hospital Capital Medical University; Capital Medical University Beijing Chaoyang Hospital